Investor Presentaiton
Investor presentation
First three months of 2017
Steady prescription uptake for SaxendaⓇ in the US
Prescription volume uptake of anti-obesity
medications (AOM) recently launched in the US
TRX
ContraveⓇ®
QsymiaⓇ
-
BelviqⓇ
SaxendaⓇ
Volume (000)
80
70
60
50
40
30
20
10
0
Feb
2016
Source: IMS NPA TRx, monthly, February 2017
changing
diabetes®
61
32
28
17
Feb
2017
Slide 86
•
Key observations
SaxendaⓇ has been launched in 18 markets including the
US, Canada, Australia, Russia, UAE, Israel, Germany,
Denmark, Sweden, Switzerland, Italy, Spain, Belgium,
Luxembourg, UK, Brazil, Chile and Mexico
· Saxenda is the leader in value market share at ~49%
among the branded AOMs in the US
While competitors promotional efforts have been erratic,
Novo Nordisk remains confident in the long-term obesity
market growth and the evolving Novo Nordisk obesity
portfolio
novo nordiskView entire presentation